Cargando…

Non-dietary methods in the treatment of celiac disease

This is a selective review of the literature concerning the methods of celiac disease treatment, which can be an alternative to a gluten-free diet. The most advanced studies are devoted to the larazotide acetate (AT-1001, human zonulin inhibitor) and prolyl-endopeptidases degrading toxic gluten pept...

Descripción completa

Detalles Bibliográficos
Autor principal: Szaflarska-Popławska, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4411409/
https://www.ncbi.nlm.nih.gov/pubmed/25960809
http://dx.doi.org/10.5114/pg.2014.47503
_version_ 1782368465703665664
author Szaflarska-Popławska, Anna
author_facet Szaflarska-Popławska, Anna
author_sort Szaflarska-Popławska, Anna
collection PubMed
description This is a selective review of the literature concerning the methods of celiac disease treatment, which can be an alternative to a gluten-free diet. The most advanced studies are devoted to the larazotide acetate (AT-1001, human zonulin inhibitor) and prolyl-endopeptidases degrading toxic gluten peptides (ALV003, AN-PEP). It is estimated that they will be registered within a few years. They will not become an alternative to the gluten-free diet but rather a supplement to it, which will enable patients to ease the nutritional restrictions.
format Online
Article
Text
id pubmed-4411409
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-44114092015-05-08 Non-dietary methods in the treatment of celiac disease Szaflarska-Popławska, Anna Prz Gastroenterol Review Paper This is a selective review of the literature concerning the methods of celiac disease treatment, which can be an alternative to a gluten-free diet. The most advanced studies are devoted to the larazotide acetate (AT-1001, human zonulin inhibitor) and prolyl-endopeptidases degrading toxic gluten peptides (ALV003, AN-PEP). It is estimated that they will be registered within a few years. They will not become an alternative to the gluten-free diet but rather a supplement to it, which will enable patients to ease the nutritional restrictions. Termedia Publishing House 2015-01-14 2015 /pmc/articles/PMC4411409/ /pubmed/25960809 http://dx.doi.org/10.5114/pg.2014.47503 Text en Copyright © 2015 Termedia http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License, permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Paper
Szaflarska-Popławska, Anna
Non-dietary methods in the treatment of celiac disease
title Non-dietary methods in the treatment of celiac disease
title_full Non-dietary methods in the treatment of celiac disease
title_fullStr Non-dietary methods in the treatment of celiac disease
title_full_unstemmed Non-dietary methods in the treatment of celiac disease
title_short Non-dietary methods in the treatment of celiac disease
title_sort non-dietary methods in the treatment of celiac disease
topic Review Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4411409/
https://www.ncbi.nlm.nih.gov/pubmed/25960809
http://dx.doi.org/10.5114/pg.2014.47503
work_keys_str_mv AT szaflarskapopławskaanna nondietarymethodsinthetreatmentofceliacdisease